AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 141 min read$AMLX

Klee Justin B. sold $980K of AMLX

Klee Justin B. (Co-Chief Executive Officer) sold 30,464 shares of Amylyx Pharmaceuticals, Inc. (AMLX) at an average of $32.18 ($32.13–$33.16, $0.98M total) across 2 trades on 2026-09-10.

Original reporting
SEC EDGAR · Klee Justin B.
Published Sep 14, 2026, 8:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 14, 2026, 8:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$AMLX
Neutral
medium confidence
Mentioned
$AMLX
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AMLXNeutralLow
01

Why it matters

The sale reduces insider ownership but does not indicate a strategic shift.

02

Market read

Routine insider transaction with modest size; limited trading relevance.

03

What to watch

Potential upcoming clinical data releases or partnership news not disclosed in filing.

Relevance 5/10Novelty 4/10Timing: post filing on 2026-09-14

Background

Form 4 disclosures provide transparent reporting of insider transactions required by the SEC.

Company-level read

Ticker impact

$AMLXNeutralMedium confidence
Context

Co-CEO Justin B. Klee sold 30,464 shares for $980K on 2026-09-10, reducing his stake to 3,613,056 shares.

Expected impact

Potential short-term pressure on AMLX price, likely limited to a few percent.

Evidence & confidence

Form 4 filing is primary source; sale amount under $1M for a co-CEO is material enough to attract attention but not large enough to drive a major move.

Market effects

Sector

Minimal impact on biotech sector; insider activity is routine.

Regional

No regional effect.

Global

Limited to AMLX investors.

Counterpoint

What could challenge this read

Insider sell could be unrelated to company fundamentals; price may remain stable.

Key entities

  • Executive
    Justin B. Klee

    Co-CEO and Director of Amylyx Pharmaceuticals.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

AMLX insider trading history →

Related articles

SEP 18
$AMLXHighAI 8/10

Amylyx Stock Tumbles As Rally Meets Dilution Jitters

Amylyx Pharmaceuticals (AMLX) shares fell as investors took profits after a rally driven by positive Phase 3 data for avexitide. Concerns include valuation, dilution from a $500M stock offering, and insider sales. The company faces high funding needs for commercialization around 2027, shifting focus to financial costs and capital access.

tipranks.com2 min
SEP 12
$AMLXHigh

Why Is AMLX Stock Popping 14% After Hours?

Amylyx Pharmaceuticals (AMLX) shares rose 14% after-hours as it prepares to release Phase 3 trial results for avexitide, its lead drug candidate for post-bariatric hypoglycemia. The trial's success could support a 2027 regulatory filing. AMLX has no FDA-approved therapies currently, and its cash runway extends into 2028. Mizuho raised its price target to $30, citing potential launch pricing updates.

stocktwits.com1 min
SEP 1
$AMLXMedAI 8/10

Is GLP-1 Stock Amylyx Still a Buy After Skyrocketing 247%?

Amylyx Pharmaceuticals (AMLX) has surged 247% this year after positive trial results for its experimental treatment, avexitide, which met all endpoints. The company aims to submit avexitide for FDA approval by year-end, with analysts estimating $1.5B in peak U.S. sales. Amylyx recently raised $500M through a stock offering. The stock is trading at $34.74, with a market cap of $4.2B.

fool.com2 min
SEP 1
$AMLXHighAI 8/10

1 Stock Amylyx Still a Buy After Skyrocketing 247%?

Amylyx Pharmaceuticals (AMLX) raised $500M, strengthening its balance sheet. Its experimental drug, avexitide, reduced serious hypoglycemic events by 55% in a phase 3 trial, with potential FDA submission by year-end. Analysts estimate peak U.S. sales at $1.5B. The stock has surged 247% year-to-date, but analysts suggest a pullback to $28-$30 per share for better entry.

aol.com2 min